[Use of monoclonal antibodies in the treatment of cancer].
Monoclonal antibodies directed against antigens borne by tumors have already been the object of clinical trials in patients with leukemia or solid tumors. These antibodies, generally obtained from murine hybridomask, are used alone or as immunoconjugates, i.e. coupled to a non-specific antimitotic agent. Under the proper conditions they may be administered with a satisfactory clinical and biological tolerance. The antimitotic action of these antibodies, which is specifically directed against neoplastic cells, has been demonstrated in vitro and in animal models and is found inconstantly in leukemias. Studies have been performed in patients bearing solid tumors, with large initial tumoral mass, showing partial regression in a few cases. A number of parameters, including modalities of administration, types of immunoconjugates and mechanisms of action in vivo, must be explored to increase the antineoplastic potential of monoclonal antibodies.
D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D006825:Hybridomas / Q000502:physiology; D007130:Immunoglobulin Idiotypes / Q000276:immunology; D007167:Immunotherapy / Q000379:methods; D008214:Lymphocytes / Q000032:analysis; D009369:Neoplasms / Q000188:drug therapy*; D012074:Remission Induction
D000911:Antibodies, Monoclonal; D007130:Immunoglobulin Idiotypes
Utilisation des anticorps monoclonaux dans le traitement du cancer.